Literature DB >> 3348614

Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum.

J Schwartz1, L Jauregui, J Lettieri, K Bachmann.   

Abstract

The effect of a multiple-dose regimen of oral ciprofloxacin (750 mg every 12 h for 11 doses) on the clearance and steady-state concentrations of theophylline in trough (predose) serum was evaluated in nine healthy male subjects, each serving as his own control. Theophylline was taken as a sustained release tablet per os in a dose of 200 mg every 12 h for 19 doses. Theophylline concentrations in serum were measured immediately before each theophylline dose. Ciprofloxacin was administered on study day 4 through the first dose of study day 8. Theophylline concentrations in serum were also measured on study days 3, 6, 8, and 10 at the following times after the first dose of each day: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 10, and 12 h. Steady-state theophylline concentrations in trough serum were significantly higher during ciprofloxacin treatment (day 8) than before (day 3) or after (day 10) ciprofloxacin administration (P less than 0.01). Likewise, theophylline clearance was significantly slower (P less than 0.01) during ciprofloxacin treatment (day 8) than before it (day 3) or after it (day 10). The magnitude of ciprofloxacin-induced changes was approximately 30%. These results suggest that a multidose regimen of ciprofloxacin significantly slows the clearance of theophylline and elevates theophylline concentrations in serum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348614      PMCID: PMC172101          DOI: 10.1128/AAC.32.1.75

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients.

Authors:  M E Wood; A C Newland
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

2.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

3.  Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.

Authors:  T T Rubio; C Shapiro
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

4.  Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.

Authors:  C M Wollschlager; S Raoof; F A Khan; J J Guarneri; V LaBombardi; Q Afzal
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Enoxacin decreases the clearance of theophylline in man.

Authors:  W J Wijnands; T B Vree; C L Van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

7.  The influence of quinolone derivatives on theophylline clearance.

Authors:  W J Wijnands; T B Vree; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

8.  Ciprofloxacin for soft tissue infections.

Authors:  M J Wood; M N Logan
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green.

Authors:  D E Nix; J M DeVito; M A Whitbread; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

  9 in total
  32 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Lack of effect of flosequinan on the pharmacokinetics of theophylline.

Authors:  F Kamali; C Edwards; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  Effects of ciprofloxacin on testosterone and cortisol concentrations in healthy males.

Authors:  N M Waite; D J Edwards; W S Arnott; L H Warbasse
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

5.  The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

Authors:  K T Batty; T M Davis; K F Ilett; L J Dusci; S R Langton
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 6.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

Review 7.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Interaction between oral ciprofloxacin and caffeine in normal volunteers.

Authors:  D P Healy; R E Polk; L Kanawati; D T Rock; M L Mooney
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs.

Authors:  M J Novotny; D H Shaw
Journal:  Can J Vet Res       Date:  1991-04       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.